Kite CAR-T gets FDA priority review, Juno shares fall – Reuters
|
Kite CAR–T gets FDA priority review, Juno shares fall
Reuters The drug is a chimeric antigen receptor T–cell (CAR-T) therapy, developed using a complicated process of extracting immune system T cells from an individual patient, altering their DNA to sharpen their ability to spot and kill cancer cells, and … |
